Alzheimer’s disease as the most common neurodegenerative disorder places enormous financial demands on our society that is increasingly focussed on the cost-effectiveness of treatment and care. The present article reflects on central information drawn from four autobiographical texts written by patients in the early stage of dementia, elucidating their needs relating to, first, the medication they rely on and, second, the importance of a healthy doctor–patient relationship. Their comments and feelings are placed in the context of clinical practice and current health care policy pertaining to our dealing with dementia, thus, contributing to ongoing discussions relating to the suitability of current health care structures in view of challenging demographic changes.
Alzheimer’s disease Dementia Life writing Cost-effectiveness Quality of care
This is a preview of subscription content, log in to check access.
The author is grateful to J. Klein for welcoming interdisciplinary approaches and to S.P. Brown for continuous discussion and encouragement. The study was entirely self-funded and there is no conflict of interest to be declared.
Michel JP, Zekry D, Mulligan R, Giacobini E, Gold G (2001) Economic considerations of Alzheimer’s disease and related disorders. Aging 13(3):255–260PubMedGoogle Scholar
Garrard P, Maloney LM, Hodges JR, Patterson K (2005) The effects of very early Alzheimer’s disease on the characteristics of writing by a renowned author. Brain 128(Pt 2):250–260PubMedGoogle Scholar
Irigaray L (1973) Le langage des déments. Mouton, The HagueGoogle Scholar
Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66(2):137–147PubMedCrossRefGoogle Scholar
Zimmermann M, Gardoni F, Di Luca M (2005) Molecular rationale for the pharmacological treatment of Alzheimer’s disease. Drugs Aging 22(Suppl 1):27–37PubMedCrossRefGoogle Scholar
Ringman JM, Cummings JL (2006) Current and emerging pharmacological treatment options for dementia. Behav Neurol 17(1):5–16PubMedGoogle Scholar
Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E et al (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363(9427):2105–2115PubMedCrossRefGoogle Scholar
Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10(1):14PubMedCrossRefGoogle Scholar
Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M (2002) Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzhelmer’s disease. Cell Mol Biol (Noisy -le-grand) 48(6):613–623Google Scholar
Pratico D (2008) Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147:70–78PubMedCrossRefGoogle Scholar